Ryan K.Walsh

Partner

Atlanta + 1.404.581.8487

Connect:

Share

Ryan Walsh is a trial lawyer with over 20 years of experience enforcing and defending clients' rights in patent and other high-stakes technology litigation. He serves as co-chair of intellectual property litigation for Jones Day's global IP practice.

Ryan excels at taking the most complex technical and legal issues and making them digestible and relatable to judges and juries. While Ryan regularly defends clients accused of infringement by competitors and nonpracticing entities, he also has extensive experience enforcing clients' patent and other intellectual property rights. He has first chair experience in some of the most active patent venues in the United States, including the International Trade Commission.

His work in the patent and trade secret space has involved a wide range of disciplines, including wireless communications, Internet of Things, medical devices, software, advanced polymers, smart grid, cable television, interactive internet web pages, printer/copier, wireless sensor networks, glucose monitoring, and portable oxygen concentrators.

Ryan has litigated copyright cases involving software, musical compositions, carpet design, and other original works, and he has experience with offensive and defensive temporary restraining order (TRO)/preliminary injunction proceedings in trade secret and Lanham Act cases. Ryan has also litigated alleged violations of the Computer Fraud and Abuse Act (CFAA).

Ryan is an active leader in the Atlanta legal community. He is a former president of both the Atlanta Bar Association and the Atlanta Legal Aid Society and currently serves on the board for the Atlanta Bar Foundation and the Georgia Intellectual Property Alliance.

Experience

  • Home Depot wins ITC trial in patent litigation relating to filament LED technologyJones Day successfully defended The Home Depot, Inc. before the International Trade Commission (ITC) against multi-patent litigation asserted by The Regents of the University of California.
  • Ricoh USA defends infringement claims involving 19 patents relating to office printer technologyJones Day is defending Ricoh USA, Inc. in a series of patent infringement cases involving office and production printer technology.
  • Home Depot obtains early dismissal in software license disputeJones Day obtained early dismissal of a lawsuit brought by software vendor Mi9 Retail, Inc. against The Home Depot, Inc. and its affiliates, including Home Depot Mexico.
  • Specialty engineered woods manufacturer reaches settlement in trade secret and supply agreement disputeJones Day represented an industry leader in the manufacture of specialty engineered wood products in a lawsuit against a supplier involving allegations of misappropriation of trade secrets, breach of contract, tortious interference, and unfair competition.
  • Global chemical company protects trade secrets, obtains judgment, damages, and attorneys' fees against former employeeJones Day assisted a global chemical company in pursuing claims of trade secret misappropriation and violations of the Computer Fraud and Abuse Act ("CFAA") against a former employee when the company discovered the employee had been systematically downloading decades of its trade secrets and confidential information.
  • Monster obtains Second Circuit affirmance of trial court victory in multimillion dollar fees lawsuit brought by investment bank over engagement letter disputeJones Day obtained an appellate victory for technology company Monster Worldwide, Inc., which runs the online recruiting and employment website Monster.com, against Stone Key Partners LLC's claims for millions of dollars in alleged fees and expenses.
  • Idenix wins $2.54 billion jury verdict in Gilead patent dispute involving hepatitis C drugsAfter a nine day trial and less than two hours of jury deliberation, Jones Day, on behalf of Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co.), won the largest patent infringement verdict in U.S. history to date, involving a multi-billion dollar patent dispute with Gilead Sciences Inc. over sofosbuvir, the active ingredient in Gilead’s hepatitis C drugs Sovaldi® and Harvoni®.
  • Jones Day secures dependency order for unaccompanied minorJones Day represented the uncle of a child, age 17, who had emigrated from Guatemala to the United States fleeing gang violence, sexual assault, hardship, and poverty.
  • Randstad acquires Monster for $429 millionJones Day advised Randstad Holding nv (AMS: RAND), a leading human resources services provider, in the acquisition of Monster Worldwide, Inc. (NYSE: MWW).
  • HD Supply secures early dismissal from NPE patent infringement caseJones Day secured an early dismissal for HD Supply, Inc. in a patent infringement case involving interactive web page technology.
    • View All

    March/April 2022 External Publications

    Navigating Trade Secret Identification During Discovery: Timing and Scope, IP Litigator

    December 2021 White Paper

    Navigating Trade Secret Identification During Discovery: Timing & Scope

    Speaking Engagements

    • October 22, 2018
      Employees and IP: Avoiding Pitfalls for the Unwary, The 12th Annual Corporate IP Institute
    • September 21, 2018
      Patent Venue Landscape One Year After TC Heartland 24th Annual Intellectual Property Institute
    • January 22, 2018
      The Odd Couple: What Companies Need to Know About IP & Tax Before Creating or Shifting IP Offshore, Jones Day CLE Academy
    • February 13, 2017
      Open Lines: How Professionalism Improves Communication and Fosters Stronger Client Relationships, Jones Day CLE Academy
    • September 16, 2016
      The Impact of Recent Supreme Court and Federal Circuit Decisions on Patent Infringement Litigation Strategies, 22nd Annual Intellectual Property Law Institute
    • February 22, 2016
      The Shifting Landscape of Patent Litigation, Jones Day CLE Academy

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.